Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Expert Opinion on Investigational Drugs|June 7, 2012
Immunomodulatory agents in myelofibrosisAli Tabarroki, Ramon V Tiu
Translational Medicine @ Unisa|April 30, 2014
Molecular genetics of myelofibrosis and its associated disease phenotypesAli Tabarroki, Ramon V Tiu
Pediatric Nephrology (Berlin, Germany)|September 9, 2006
Prognosis of acute renal failure in childrenHasan Otukesh, Rozita Hoseini, Nakissa Hooman, et al.
Journal of Nephrology|October 25, 2008
Short-term and long-term outcome of hemolytic uremic syndrome in Iranian childrenHasan Otukesh, Rozita Hoseini, Pedram Golnari, et al.
SAGE Open Medical Case Reports|August 5, 2016
A case of mistaken identity: When lupus masquerades as primary myelofibrosisEdy Hasrouni, Heesun J Rogers, Ali Tabarroki, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 16, 2015
Non-t(6;9) and Non-Inv(3) Balanced Chromosomal Rearrangements Are Associated With Poor Survival Outcomes in Myelodysplastic SyndromesJing Ai, Valeria Visconte, Ali Tabarroki, et al.
Journal of Hematology & Oncology|December 8, 2014
Splicing factor 3b subunit 1 (Sf3b1) haploinsufficient mice display features of low risk Myelodysplastic syndromes with ring sideroblastsValeria Visconte, Ali Tabarroki, Li Zhang, et al.
American Journal of Hematology|January 23, 2016
Impact of allogeneic hematopoietic cell transplant in patients with myeloid neoplasms carrying spliceosomal mutationsBetty Ky Hamilton, Valeria Visconte, Xuefei Jia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2013
Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapyReda Z Mahfouz, Ania Jankowska, Quteba Ebrahem, et al.
Pageof 2